Showing results (751-760 of 1,609) with videos related to

Sort By:
Pageof 161
JAMA Oncology|October 5, 2023
Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data PackagesAshley M Hopkins, Natansh D Modi, Ahmad Y Abuhelwa, et al.
JAMA Oncology|September 28, 2023
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical TrialStuart J Wong, Pedro A Torres-Saavedra, Nabil F Saba, et al.
JAMA Oncology|October 3, 2024
Prevalence and Factors Associated With Prostate Cancer Among Transgender WomenCeleste Manfredi, Antonio Franco, Francesco Ditonno, et al.
JAMA Oncology|September 12, 2024
Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer SurvivalMahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, et al.
JAMA Oncology|June 1, 2023
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical TrialLili Mao, Bin Lian, Caili Li, et al.
JAMA Oncology|February 26, 2026
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 TrialMazyar Shadman, Michael LeBlanc, Lisa Rimsza, et al.
JAMA Oncology|February 26, 2026
First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical TrialYunpeng Yang, Chia-Jui Yen, Jianji Pan, et al.
JAMA Oncology|November 21, 2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical TrialElias Jabbour, Vivian G Oehler, Paul B Koller, et al.
JAMA Oncology|November 27, 2024
Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A ReviewJyoti Malhotra, Isa Mambetsariev, Gregory Gilmore, et al.
JAMA Oncology|October 17, 2024
Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade ReclassificationZhuo Tony Su, Mufaddal Mamawala, Patricia K Landis, et al.
Pageof 161